After accounting for misdiagnosis and treatment effect, allelespecific (AS)-PCR detects the JAK2V617F mutation in 495% of polycythemia vera (PV) patients. Using database inquiry, we identified 6 of a total 220 cases with PV that were JAK2V617F-negative (prevalence ¼ 3%). Of these, five cases (B80%) were found to harbor one of the two JAK2 exon 12 mutations (F537-K539delinsL or N542-E543del) in bone marrow (BM) and/or peripheral blood cells. Similar screening of six additional cases -three each with idiopathic erythrocytosis (IE) or otherwise unexplained erythrocytosis (UE) -did not reveal either JAK2V617F or JAK2 exon 12 mutations. We found JAK2 exon 12 mutations in PV cases to be readily detected by both DNA sequencing and AS-PCR, regardless of whether BM or peripheral blood cells were used as the source for DNA. Although erythroid hyperplasia was the predominant histologic feature on BM examination, megakaryocyte abnormalities and reticulin fibrosis were noted in most PV patients harboring exon 12 mutations. However, similar BM morphologic changes can also be seen in some JAK2V617F-positive PV cases; therefore, distinct genotype-phenotype association cannot be established.
Introduction
In early 2005, five independent groups virtually simultaneously reported the presence of a specific-activating mutation in the JH2 domain of JAK2 kinase in several myeloproliferative disorders (MPD), including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) (reviewed in Tefferi A and Gilliland DG). 1 The allelic frequency of JAK2V617F is upwards of 95% in PV, and roughly 50% in ET and PMF, as estimated by sensitive detection methodologies. 2, 3 While JAK2V617F is the predominant disease-associated allele in MPD, it is becoming clear that other alleles may also contribute to the MPD phenotype. In general, the novel allele, when present, is found in MPD cases that are JAK2V617F-negative (for example, MPLW515L/K), 4 although in rare cases, these alleles may occur in conjunction with JAK2V617F (for example, JAK2D620E and MPLW515L/K). [5] [6] [7] More recently, a novel series of somatic mutations involving the 5 0 boundary of the JAK2 JH2 domain have been described in rare cases of JAK2V617F-negative PV, or in patients with idiopathic erythrocytosis (IE). 8 In total, 4 mutant exon 12 alleles were described in 10 cases, with changes affecting the conserved residues F537 to E543. In this study, the clinical phenotype was that of relatively isolated erythrocytosis, and in some cases, the level of JAK2 exon 12 mutation in granulocytes was reported to be low, whereas the mutation was readily detected in erythropoietin-independent erythroid colonies (EEC). In this study, we examine the prevalence of JAK2 exon 12 mutations in cases of JAK2V617F-negative PV, as well as in a small cohort of cases with IE or otherwise unexplained erythrocytosis (UE). Furthermore, we describe the clinicopathologic characteristics of patients harboring exon 12 mutations for genotype-phenotype analysis.
Materials and methods

Patient accrual
The current study was approved by our Institutional Review Board. All patients provided informed consent, and research was carried out according to the principles of the Declaration of Helsinki. We identified consecutive PV patients by database inquiry based on availability of both clinical and laboratory information at diagnosis and archived bone marrow (BM), collected either at the time of diagnosis or during the chronic phase of the disease. Clinical and laboratory data for all patients were reviewed by AP and AT, and PV was classified according to World Health Organization (WHO) criteria. 9 We used a combination of database inquiry and physician survey to identify six additional cases with sustained increase in hemoglobin (418.5 g/dl for men; 416.5 g/dl for women) who did not meet conventional criteria for PV -of these, three patients with increased red cell mass met criteria for IE; three other patients with similar presentation did not have red cell mass measured and were labeled as 'unexplained erythrocytosis' (UE). Peripheral blood and BM aspirate and biopsy slides for five PV patients (excluding case 4) were available for morphologic review.
Sample collection and processing DNA was extracted from peripheral blood mononuclear cells (PBMC), granulocytes, or BM cells as described previously. 10 DNA was quantified by spectrophotometry (NanoDrop Technologies Inc., Wilmington, DE, USA) and stored in 25 ng/ml aliquots for PCR analysis.
JAK2V617 mutation screening: allele-specific (AS)-qPCR assay
We used primers and probes as described previously by Levine et al. 2 Primers were purchased from Integrated DNA Techno- 
JAK2 exon 12 mutation screening
We used previously published primers to amplify exon 12. 8 The PCR mix included: 5 ml of 10 Â PCR buffer (Roche-AppliedScience, Indianapolis, IN, USA), 1U Taq Polymerase (RocheApplied-Science), 400 nM each of forward and reverse primer, 300 mM of each deoxynucleoside triphosphate (dNTP), 100 ng of DNA template, and H 2 O, to a final reaction volume of 50 ml. 
Results and discussion
Through database inquiry, we identified 220 consecutive patients with PV seen at our institution, for whom complete clinical and laboratory information was available. Of these, six PV cases (B3%) were found to be JAK2V617F-negative by AS-PCR (sensitivity of mutant allele detectionp1%), which is consistent with published estimates of JAK2V617F prevalence in this population. 2, 3 Of the six PV cases without JAK2V617F, five (B80%) were found to harbor JAK2 exon 12 mutations; either F537-K539delinsL (n ¼ 3) or N542-E543del (n ¼ 2) ( Table 1) . Table 1 Clinical and laboratory features at presentation for the six patients with JAK2V617F-negative polycythemia vera The M/E ratio was determined from the BM aspirate differential and confirmed by evaluation of the BM biopsy.
g Reticulin fibrosis at time of presentation/at time of transformation to myelofibrosis.
JAK2 exon 12 mutations in polycythemia vera A Pardanani et al
Neither of the two other previously reported JAK2 exon 12 mutations (H538QK539L and K539L) were detected in the current study. 8 In all cases harboring JAK2 exon 12 mutations, the mutant allele was readily identified by PCR sequencing in either BM cells (5 of 5 cases), peripheral blood granulocytes (2 of 2 cases) and/or PBMC (1 of 3 cases; Table 1 ). We used AS-PCR assays to exclude presence of all known exon 12 mutations at low levels (that is, below the threshold of detection by PCR sequencing; o5-10%) in situations where the initial screening for the mutations was negative (Tables 1 and 2 ). For the sole PV patient (PV6) without detectable exon 12 mutations by either PCR sequencing or AS-PCR, individual EEC could not be genotyped owing to unavailability of viable cells for this assay; thus, the possibility that EEC cells harbor such mutations cannot be definitively excluded for this patient.
For the two cases (PV3 and PV4) where granulocytes and PBMC could be concurrently screened, the exon 12 mutations were identified in PBMC only with AS-PCR, while the mutations were readily detected in granulocytes by PCR sequencing (Table 1) . These results suggest that, as reported previously for JAK2V617F, exon 12 mutations may predominantly involve myeloid-lineage cells, although additional studies are needed to confirm these findings. [11] [12] [13] Consistent with findings reported by Scott et al., 8 sequencing of DNA from bulk granulocytes, PBMC or BM cells revealed a heterozygous pattern in all five cases harboring exon 12 mutations -such an analysis however does not reveal the mutation pattern at the individual cell level.
BM aspirates and trephine biopsies for the exon 12 mutationharboring patients (PV1 to PV5) were collected either at diagnosis or in the chronic phase of disease. Examination of the BM aspirates and biopsies confirmed the presence of characteristic erythroid hyperplasia in all cases; two cases (PV1 and PV3) had 480% erythroid precursors identified in their marrow aspirates and confirmed by histologic review of the respective biopsy specimens (Figure 1a) . The remaining two cases with exon 12 mutations that were available for review demonstrated both an erythroid and granulocytic hyperplasia in their marrow aspirates and biopsies, although the erythroid component was the predominant lineage. Megakaryocytes were increased in all four cases reviewed (Table 1) . Loose clusters of megakaryocytes were easily identified in three of the exon 12 mutation-positive biopsies, but no clusters were seen in the remaining positive case. Tight cell-to-cell clustering was not seen in any of these cases. Abnormal megakaryocytes were recognized in all four cases and showed abnormal nuclear lobulation, a dispersed chromatin pattern and occasional eosinophilic nucleoli; in two cases abnormally large megakaryocytes with hyperchromatic nuclei were identified (Figures 1b  and c) . We also observed an increase in marrow reticulin fibers in two of the exon 12 mutation-positive cases at the time of initial biopsy ( Figure 1d) ; the specimen obtained from the patient who evolved into post-polycythemic myelofibrosis (PV2) showed significant fibrosis at that time, and osteosclerosis was also observed (Table 1) . In striking contrast, the sole PV patient without identifiable JAK2 exon 12 mutations (PV6), exhibited characteristic histologic features of PV, including panhyperplasia with significant megakaryocyte atypia and clustering, as well as increased reticulin fibrosis.
We identified six additional cases with erythrocytosis who did not satisfy conventional criteria for diagnosing PV (three patients each had IE and UE -all were JAK2V617F-negative; Table 2 ). Screening for presence of JAK2 exon 12 mutations was of interest given that such patients are encountered in clinical practice, and since, in Scott et al. 8 report, 4 of the 10 patients with such mutations were deemed to have IE. In the current study, none of the six IE/UE patients harbored JAK2 exon 12 mutations, thus pointing to the need for additional studies to establish the true mutation frequency in this population.
We have noted predominant erythroid hyperplasia with relative sparing of other lineages in rare PV cases with low JAK2V617F allele burden (A Tefferi and CA Hanson, unpublished observations). Since the size of the mutant clone may contribute to phenotype and since some patients with JAK2 exon Table 2 Clinical and laboratory features at presentation for the three patients each with JAK2 V617F-negative idiopathic erythrocytosis or unexplained erythrocytosis 12 mutations have a low mutation level in peripheral blood, we compared BM histology of two PV cases with JAK2V617F allele burdens of 1 and 3%, with that of PV patients harboring exon 12 mutations (above), to clarify genotype-phenotype correlations. We found BM histology to be very similar in both groups, which suggests that any conclusions regarding genotype-phenotype correlations in PV may be premature at this time (data not shown).
In summary, we found the majority but not all patients with JAK2V617F-negative PV to harbor exon 12 mutations in BM and peripheral blood. These patients displayed predominant erythroid hyperplasia with more subtle involvement of other lineages; however, these morphologic findings may not be specific for exon 12 mutations.
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